Video

CGRP drugs: How is it going?


 

REPORTING FROM HCNE STOWE 2019

– These are the early days of the “CGRP monoclonal antibody era,” Peter McAllister, MD, said in a summary of the current status of calcitonin gene-related peptide monoclonal antibodies for migraine prevention. He discussed what has been learned in the clinical trials of these drugs as well as in the first 10 months of having them on the market.

Vidyard Video

In an interview at the annual meeting of the Headache Cooperative of New England, Dr. McAllister said, “We are comforted that we have now 1-year, 3-year, and 5-year data” from clinical trials, but the sample size is small.

In the time since the first three drugs were approved, “we have probably in the ballpark of over 200,000 patients who have received a monoclonal antibody, and so far there has been nothing that makes us stop cold in our tracks and say there’s something wrong here. That is very comforting,” he said. Dr. McAllister is the medical director of the New England Institute for Neurology and Headache in Stamford, Conn.

What is still unknown, however, is the long-term safety and efficacy; what happens in a larger pool of patients taking these drugs; what happens in pregnancy and effects on the fetus; how and when to safely switch from one monoclonal antibody to another; the systemic effects of these drugs; and other concerns that may arise in postmarketing studies.

Recommended Reading

Antibody cleared amyloid plaques, slowed cognitive decline
MDedge Internal Medicine
Positive pivotal trials for new headache drugs abound
MDedge Internal Medicine
What to expect from next-gen CGRP inhibitors for migraine, cluster headache
MDedge Internal Medicine
Spontaneous intracranial hypotension: a triple misnomer
MDedge Internal Medicine
FDA approves Ajovy for migraine prevention
MDedge Internal Medicine
Study: Problems persist with APMs
MDedge Internal Medicine
Increased risk of atrial fibrillation with migraine aura
MDedge Internal Medicine
Active migraine in women linked to lower risk of developing T2DM
MDedge Internal Medicine
Age of migraine onset may affect stroke risk
MDedge Internal Medicine
International survey probes oxygen’s efficacy for cluster headache
MDedge Internal Medicine